Finally, in 2016, the study institution piloted a clinical trial evaluating the safety and efficacy of SLNB omission for patients 65 years of age or older with ER+, HER2–, T1-T2 IBC. The gene discussed is ESR1; the disease is inflammatory breast carcinoma.